INT76625

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 1998
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 14
Total Number 14
Disease Relevance 5.10
Pain Relevance 3.49

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (Phc1) DNA binding (Phc1)
Anatomy Link Frequency
plasma 1
brain 1
external 1
synapse 1
Phc1 (Mus musculus)
Pain Link Frequency Relevance Heat
Dopamine 317 99.96 Very High Very High Very High
noradrenaline 49 98.12 Very High Very High Very High
anesthesia 4 96.16 Very High Very High Very High
Locus ceruleus 14 95.64 Very High Very High Very High
antagonist 9 95.56 Very High Very High Very High
monoamine 5 95.56 Very High Very High Very High
headache 13 92.48 High High
Neurotransmitter 25 88.60 High High
agonist 14 87.28 High High
fluoxetine 2 87.28 High High
Disease Link Frequency Relevance Heat
Cognitive Disorder 57 99.98 Very High Very High Very High
Attention Deficit Hyperactivity Disorder 693 99.80 Very High Very High Very High
Convulsion 5 99.60 Very High Very High Very High
Epilepsy 7 99.04 Very High Very High Very High
Glaucoma 4 98.48 Very High Very High Very High
Thyroid Disease 3 98.08 Very High Very High Very High
Hypertension 3 97.40 Very High Very High Very High
Psychosis 17 96.84 Very High Very High Very High
Vomiting 6 93.56 High High
Anxiety 5 93.34 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Permeation of MPH was increased in the presence of 100 mM GC with an enhancement factor of 9.3 whereas no enhancement was obtained with 10 mM GC.
Positive_regulation (increased) of MPH
1) Confidence 0.36 Published 1998 Journal J Control Release Section Abstract Doc Link 9685907 Disease Relevance 0 Pain Relevance 0.34
Repeated contractions with norepinephrine (NE) 0.1 microM after stabilization altered neither the contraction nor the EDR induced by acetylcholine (Ach) 1 microM.
Neg (neither) Positive_regulation (induced) of EDR
2) Confidence 0.20 Published 2001 Journal Endothelium Section Abstract Doc Link 11824475 Disease Relevance 0 Pain Relevance 0.24
Therefore, MPH-induced blockade of the DAT increases dopamine concentrations in the synapse and extracellular space [56].
Positive_regulation (increases) of MPH in synapse associated with dopamine
3) Confidence 0.09 Published 2008 Journal Current Neuropharmacology Section Body Doc Link PMC2701285 Disease Relevance 0.15 Pain Relevance 0.46
Although it cannot be said with certainty that the cognitive-enhancing MPH effects actually did occur in the PFC, Berridge et al. [5] provide additional animal data supporting this hypothesis.
Positive_regulation (enhancing) of MPH associated with cognitive disorder
4) Confidence 0.08 Published 2008 Journal Current Neuropharmacology Section Body Doc Link PMC2701285 Disease Relevance 0.35 Pain Relevance 0.48
Indirect support for MPH’s noradrenergic actions also comes from the finding that ADHD symptoms can be recreated by blocking ?
Positive_regulation (support) of MPH associated with attention deficit hyperactivity disorder
5) Confidence 0.08 Published 2008 Journal Current Neuropharmacology Section Body Doc Link PMC2701285 Disease Relevance 0.60 Pain Relevance 0.55
These results indicate that MPH is highly effective for the treatment of adults with ADHD when delivered in appropriate doses and dosed across the day.
Positive_regulation (effective) of MPH associated with attention deficit hyperactivity disorder
6) Confidence 0.08 Published 2007 Journal BMC Psychiatry Section Body Doc Link PMC2075491 Disease Relevance 0.43 Pain Relevance 0
This is so because the abuse potential of MPH is thought to be due to the rapid onset of blockade of the presynaptic dopamine transporter (DAT) in the brain [22].
Positive_regulation (potential) of MPH in brain associated with dopamine
7) Confidence 0.07 Published 2007 Journal BMC Psychiatry Section Body Doc Link PMC2075491 Disease Relevance 0.38 Pain Relevance 0.08
The results suggest that the concurrent administration of racemic (i.e. dl-) MPH with aripiprazole significantly increased the plasma concentrations of both total MPH as well as the less active l-isomer.
Positive_regulation (increased) of MPH in plasma
8) Confidence 0.06 Published 2010 Journal Toxicology Section Abstract Doc Link 20097249 Disease Relevance 0 Pain Relevance 0.09
Also, it should be noted that the effect of the 5-HTTLPR genotype remained significant after controlling for the effect of the 3'UTR VNTR polymorphism of the dopamine transporter gene, which was previously reported to be associated with response to MPH [5,6].
Positive_regulation (response) of MPH associated with dopamine
9) Confidence 0.06 Published 2010 Journal BMC Psychiatry Section Body Doc Link PMC2905344 Disease Relevance 0.13 Pain Relevance 0.05
Similar to other stimulants, MPH can cause mild disturbances in mood, appetite and sleep which can be minimized by using the lowest effective dose and using long-acting preparations.2,17,32,33 The most common side effects of long-acting preparations include headache, decreased appetite, insomnia, nervousness and nausea.32,55,56 Patients appear to be fairly tolerant of side effects, one study showing only 4.3% of patients treated with OROS MPH discontinuing treatment due to an adverse event.55 MPH preparations should be used with caution in patients with prior history of seizure disorders as it can initiate seizures in higher doses.33 MPH and other stimulants are contraindicated in patients with glaucoma, hyperthyroidism, hypertension, acute psychosis and those using monoamine oxidase inhibitors.33
Positive_regulation (stimulants) of MPH associated with vomiting, glaucoma, epilepsy, convulsion, psychosis, hypertension, thyroid disease, headache, anxiety, sleep disorders and monoamine
10) Confidence 0.04 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2732009 Disease Relevance 1.40 Pain Relevance 0.48
Long-acting preparations have a similar efficacy rate with greater convenience and compliance due to single daily dosing.32,55–59 In one study, once daily dosing of equipotent extended-release OROS MPH tablets (Concerta®) had similar efficacy to 3 times per day dosing of immediate-release MPH.59 In a double-blind trial of 401 adults with ADHD, those treated with OROS methylphenidate (18 mg, 36 mg, or 72 mg/day), demonstrated significant improvement in total symptom score as measured by Connor’s Adult ADHD Rating Scale (mean change = ?
Positive_regulation (immediate-release) of MPH associated with attention deficit hyperactivity disorder
11) Confidence 0.04 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2732009 Disease Relevance 0.52 Pain Relevance 0.03
Further, approximately 11% of students without ADHD reported using MPH or amphetamine for recreational purposes.70
Positive_regulation (using) of MPH associated with attention deficit hyperactivity disorder
12) Confidence 0.04 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2732009 Disease Relevance 0.95 Pain Relevance 0.10
The reversal potential of I(MPH) was changed by 54 mV per decade change in the external K(+) concentration.
Positive_regulation (changed) of MPH in external
13) Confidence 0.03 Published 2002 Journal J. Neurophysiol. Section Abstract Doc Link 11877494 Disease Relevance 0.14 Pain Relevance 0.45
It comes as a 20 mg sustained released tablet that results in a release of about 7 mg of short-acting MPH over several hours.
Positive_regulation (acting) of MPH
14) Confidence 0.02 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695228 Disease Relevance 0.06 Pain Relevance 0.14

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox